Camrelizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Camrelizumab comprises 256 peer-reviewed publications across 15 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Hepatocellular, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, and Biliary Tract Neoplasms. Most recent publication: Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial., J Clin Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Valle J, Wasan H, Palmer DH, et al. · N Engl J Med · 2010
    PubMed: PMID 20375404 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Cholangiocarcinoma.
    Razumilava N, Gores GJ · Lancet · 2014
    PubMed: PMID 24581682 · NCT04642664 (ACABC) · Cholangiocarcinoma
  3. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
    Qin S, Ren Z, Meng Z, et al. · Lancet Oncol · 2020
    PubMed: PMID 32112738 · NCT04642664 (ACABC) · Cholangiocarcinoma
  4. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
    Li C, Tian Y, Zheng Y, et al. · J Clin Oncol · 2025
    PubMed: PMID 39383487 · NCT07026149 · Adenocarcinoma
  5. Bladder Cancer: New Insights into Its Molecular Pathology.
    Inamura K · Cancers (Basel) · 2024
    PubMed: PMID 29614760 · NCT04706598 · Urinary Bladder Neoplasms
  6. Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
    Franses JW, Hong TS, Zhu AX, et al. · Lancet Gastroenterol Hepatol · 2020
    PubMed: PMID 31109809 · NCT04642664 (ACABC) · Cholangiocarcinoma
  7. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D, Starling N, Rao S, et al. · N Engl J Med · 2008
    PubMed: PMID 18172173 · NCT04286711
  8. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
    Blay JY, Chevret S, Le Cesne A, et al. · Lancet Oncol · 2023
    PubMed: PMID 37429302 · NCT06140732 · Chordoma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT03099382Esophageal NeoplasmsOverall Survival (OS)
approximately 24 months
Camrelizumab8.28 months
Investigator's Choice of Standard Therapy6.24 months

Publications by year

1987–2026: 256 publications.

1987
1
1999
2
2000
1
2001
1
2004
3
2005
3
2006
2
2007
1
2008
4
2009
5
2010
2
2011
3
2012
3
2013
2
2014
8
2015
12
2016
10
2017
5
2018
13
2019
24
2020
21
2021
21
2022
35
2023
16
2024
22
2025
25
2026
11

Publications by indication

Carcinoma, Hepatocellular (36)

  • Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
    J Clin Oncol · 2026 · PMID 41734362 · NCT04559607
  • Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.
    BMC Cancer · 2025 · PMID 40335980 · NCT05099848
  • Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet · 2025 · PMID 41125112 · NCT04521153
  • Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.
    Clin Mol Hepatol · 2025 · PMID 39300923 · NCT07314372
  • Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet · 2025 · PMID 39798578 · NCT07157969

Nasopharyngeal Carcinoma (25)

  • Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.
    JAMA Oncol · 2026 · PMID 41609753 · NCT03707509
  • A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Cancer Med · 2024 · PMID 38205914 · NCT04143984
  • Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
    Nat Commun · 2023 · PMID 37580352 · NCT04547088
  • Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy.
    Cancer Med · 2023 · PMID 37409613 · NCT03707509
  • Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol · 2023 · PMID 36735896 · NCT04586088

Urinary Bladder Neoplasms (17)

  • Bladder Cancer: New Insights into Its Molecular Pathology.
    Cancers (Basel) · 2024 · PMID 29614760 · NCT04706598
  • Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
    J Immunother Cancer · 2019 · PMID 29368638 · NCT04706598
  • Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol · 2018 · PMID 28583311 · NCT04706598
  • [Incidence and mortality of bladder cancer in China, 2014].
    Zhonghua Zhong Liu Za Zhi · 2018 · PMID 30293387 · NCT04706598
  • Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.
    J Oncol Pract · 2018 · PMID 28796558 · NCT04706598

Biliary Tract Neoplasms (16)

  • Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study.
    Oncologist · 2024 · PMID 39102756 · NCT04720131
  • Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
    Hepatobiliary Surg Nutr · 2024 · PMID 32832493 · NCT04720131
  • Cholangiocarcinoma - evolving concepts and therapeutic strategies.
    Nat Rev Clin Oncol · 2024 · PMID 28994423 · NCT04720131
  • Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
    J Gastrointest Oncol · 2022 · PMID 31392046 · NCT04720131
  • Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Drug Deliv · 2022 · PMID 35506447 · NCT07159217

Squamous Cell Carcinoma of Head and Neck (13)

  • Immune-featured stromal niches associate with response to neoadjuvant immunotherapy in oral squamous cell carcinoma.
    Cell Rep Med · 2025 · PMID 40107247 · NCT04649476
  • Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial.
    Cell Rep Med · 2025 · PMID 39889711 · NCT04649476
  • Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
    Nat Commun · 2024 · PMID 38467604 · NCT07400094
  • Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.
    Nat Med · 2023 · PMID 37488287 · NCT06109207
  • Cancer statistics, 2023.
    CA Cancer J Clin · 2023 · PMID 36633525 · NCT06109207

Colorectal Neoplasms (12)

  • Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
    Eur J Cancer · 2023 · PMID 36628898 · NCT06148402
  • Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA Netw Open · 2022 · PMID 35179586 · NCT06148402
  • Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
    Clin Cancer Res · 2021 · PMID 32499235 · NCT04866862
  • Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Br J Cancer · 2021 · PMID 33024268 · NCT06148402
  • Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Clin Cancer Res · 2020 · PMID 30348638 · NCT04866862

Publications by journal

Trial-results highlights

The pivotal trial NCT03099382 investigated Camrelizumab in patients diagnosed with esophageal neoplasms. A primary outcome measured in this study was Overall Survival (OS). For the Camrelizumab arm in NCT03099382, the median Overall Survival reported was 8.28 months. In comparison, patients receiving Investigator's Choice of Standard Therapy within the same trial had a median Overall Survival of 6.24 months.

The Overall Survival endpoint in NCT03099382 was approximately 24 months in duration. During this period, the Camrelizumab arm demonstrated a median OS of 8.28 months. The Investigator's Choice of Standard Therapy arm in NCT03099382 reported a median OS of 6.24 months. These specific median values reflect the outcomes observed for each treatment group in this study concerning esophageal neoplasms.

All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Camrelizumab publications (256)

2026 (11 papers)

  1. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
    Zhu HD, Fan WJ, Zhao C, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41734362 · NCT04559607 · Carcinoma, Hepatocellular
  2. Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial.
    Zhang X, Sun D, Zhang Y, et al. · BMC Med · 2026 · Derived
    PubMed: PMID 41408254 · NCT04560127
  3. Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
    You R, Xu GQ, Ding X, et al. · BMJ · 2026 · Derived
    PubMed: PMID 41667193 · NCT04453826 · Nasopharyngeal Neoplasms
  4. Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study.
    Xu B, Zhu G, Lu J, et al. · Cancer Med · 2026 · Derived
    PubMed: PMID 42165088 · NCT04346381
  5. Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling.
    Tong Z, Gao L, Wang D, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41922688 · NCT04625803 · Colonic Neoplasms
  6. Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series.
    Tan H, Wang H, Zhou J, et al. · Ther Clin Risk Manag · 2026 · Derived
    PubMed: PMID 42051923 · NCT04447274 · Sarcoma
  7. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    Lei J, Zhao J, Gong L, et al. · JAMA Oncol · 2026 · Derived
    PubMed: PMID 37535377 · NCT04338620 · Carcinoma, Non-Small-Cell Lung
  8. Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.
    Huang Y, Sun D, Zhou H, et al. · JAMA Oncol · 2026 · Derived
    PubMed: PMID 41609753 · NCT03707509 · Nasopharyngeal Carcinoma
  9. Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.
    Huang SW, Liang YL, Tao YL, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41791006 · NCT03427827 (DIPPER) · Nasopharyngeal Neoplasms
  10. Consolidative Camrelizumab Following Definitive Concurrent Chemoradiation Therapy With Involved-Field Irradiation in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial.
    Cheng Y, Wang J, Lv X, et al. · Int J Radiat Oncol Biol Phys · 2026 · Derived
    PubMed: PMID 42031221 · NCT04286958 (ESCC) · Esophageal Neoplasms
  11. Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT).
    Chen M, Huang Y, Zhang S, et al. · BMC Med · 2026 · Derived
    PubMed: PMID 41803866 · NCT05176002 · Esophageal Neoplasms

2025 (25 papers)

  1. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
    Li C, Tian Y, Zheng Y, et al. · J Clin Oncol · 2025 · Trial result
    PubMed: PMID 39383487 · NCT07026149 · Adenocarcinoma
  2. Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial.
    Zhou C, Yin Y, Shangguan C, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 41121239 · NCT04932187
  3. LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer.
    Yang Z, Yu B, Hu J, et al. · Dig Dis Sci · 2025 · Derived
    PubMed: PMID 39961962 · NCT04208347 · Adenocarcinoma
  4. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.
    Yalikun K, Li Z, Zhang J, et al. · BMC Cancer · 2025 · Derived
    PubMed: PMID 40335980 · NCT05099848 · Carcinoma, Hepatocellular
  5. Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.
    Wei GX, Zhou YW, Cao P, et al. · J Transl Med · 2025 · Derived
    PubMed: PMID 41225509 · NCT05019534
  6. Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China.
    Wang Z, Sun Y, Wang Q, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 40016735 · NCT04782765
  7. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Wang Z, Fan J, Zhou S, et al. · Lancet · 2025 · Derived
    PubMed: PMID 41125112 · NCT04521153 · Carcinoma, Hepatocellular
  8. PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
    Wang Y, Lu J, Chong X, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 40082418 · NCT04609176 · Stomach Neoplasms
  9. Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC.
    Wang K, Wang X, Meng X, et al. · Ann Nucl Med · 2025 · Derived
    PubMed: PMID 40348946 · NCT06241807 · Carcinoma, Non-Small-Cell Lung
  10. Immune-featured stromal niches associate with response to neoadjuvant immunotherapy in oral squamous cell carcinoma.
    Liu YT, Liu HM, Ren JG, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 40107247 · NCT04649476 (NEOPBOSCC) · Squamous Cell Carcinoma of Head and Neck
  11. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial.
    Liu M, Qiu G, Guan W, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 39962074 · NCT05001412
  12. Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial.
    Liu HM, Xiong XP, Yu ZL, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 39889711 · NCT04649476 (NEOPBOSCC) · Squamous Cell Carcinoma of Head and Neck
  13. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study.
    Lin Z, Zhang P, Cai M, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 40346524 · NCT04231552 · Rectal Neoplasms
  14. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.
    Liang YL, Liu X, Shen LF, et al. · JAMA · 2025 · Derived
    PubMed: PMID 40079940 · NCT03427827 (DIPPER) · Nasopharyngeal Neoplasms
  15. First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial.
    Li YS, Yu Q, Bu Q, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39929333 · NCT04768075 · Carcinoma, Non-Small-Cell Lung
  16. Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial.
    Jin H, Yu J, Gao Y, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 40656603 · NCT04515615 · Stomach Neoplasms
  17. Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.
    Ji S, Sheng Z, Bian D, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 40682106 · NCT04379739 · Carcinoma, Non-Small-Cell Lung
  18. First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.
    Hou X, Zhou C, Wu G, et al. · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 41324015 · NCT04211090 (CAP-BRAIN) · Brain Neoplasms
  19. Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.
    He Y, Liu H, Li X, et al. · Eur J Cancer · 2025 · Derived
    PubMed: PMID 40834785 · NCT05355168 · Esophageal Squamous Cell Carcinoma
  20. Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma.
    Guo B, Fan Y, Li D, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 41349529 · NCT05236699 (CCGLC-005) · Cholangiocarcinoma
  21. Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
    Chen L, Li H, Zhang H, et al. · JAMA · 2025 · Derived
    PubMed: PMID 39671272 · NCT04613674 · Triple Negative Breast Neoplasms
  22. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study.
    Ai L, Li Q, Zhang S, et al. · Innovation (Camb) · 2025 · Derived
    PubMed: PMID 39872476 · NCT04346381
  23. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.
    Yang Y, Pang K, Lin G, et al. · Nat Med · 2025 · Background
    PubMed: PMID 39762418 · NCT07521605
  24. Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.
    Li B, Wen J, Xu Z, et al. · Clin Mol Hepatol · 2025 · Background
    PubMed: PMID 39300923 · NCT07314372 (FAD-HCC-001) · Carcinoma, Hepatocellular
  25. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Kudo M, Ren Z, Guo Y, et al. · Lancet · 2025 · Background
    PubMed: PMID 39798578 · NCT07157969 · Carcinoma, Hepatocellular

2024 (22 papers)

  1. Bladder Cancer: New Insights into Its Molecular Pathology.
    Inamura K · Cancers (Basel) · 2024 · Trial result
    PubMed: PMID 29614760 · NCT04706598 · Urinary Bladder Neoplasms
  2. Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.
    Zuo WJ, Chen L, Shen Y, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 38362377 · NCT05582499 (FASCINATE-N) · Triple Negative Breast Neoplasms
  3. Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial.
    Zhu YC, Wei ZG, Wang JJ, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39609453 · NCT04318730 · Adrenocortical Carcinoma
  4. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
    Zhong WJ, Lin JA, Wu CY, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 38400680 · NCT05602935 · Stomach Neoplasms
  5. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
    Ren S, Wang X, Han BH, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38388167 · NCT04346381
  6. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
    Pu X, Lin G, Xiao M, et al. · EClinicalMedicine · 2024 · Derived
    PubMed: PMID 38261958 · NCT04459078 · Adenocarcinoma of Lung
  7. Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial.
    Pan H, Yu M, Tang X, et al. · Med · 2024 · Derived
    PubMed: PMID 38417440 · NCT04805736 · Breast Neoplasms
  8. Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma.
    Nie J, Wang C, Zheng L, et al. · Blood · 2024 · Derived
    PubMed: PMID 39093981 · NCT04233294 · Hodgkin Disease
  9. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
    Liu Y, Ping L, Song Y, et al. · BMC Med · 2024 · Derived
    PubMed: PMID 38454451 · NCT04239170 · Hodgkin Disease
  10. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
    Lin JX, Tang YH, Zheng HL, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 38167806 · NCT04195828
  11. Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases.
    Li M, Chen J, Yu H, et al. · Oncoimmunology · 2024 · Derived
    PubMed: PMID 38169917 · NCT04211090 (CAP-BRAIN) · Brain Neoplasms
  12. Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study.
    Jing C, Bai Z, Tong K, et al. · Oncologist · 2024 · Derived
    PubMed: PMID 39102756 · NCT04720131 · Biliary Tract Neoplasms
  13. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.
    Huang SW, Jiang W, Xu S, et al. · Signal Transduct Target Ther · 2024 · Derived
    PubMed: PMID 39438442 · NCT03427827 (DIPPER) · Nasopharyngeal Neoplasms
  14. A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Hu J, Huang Q, Hu W, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 38205914 · NCT04143984 · Nasopharyngeal Carcinoma
  15. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M, Zhang Y, Wang Z, et al. · Invest New Drugs · 2024 · Derived
    PubMed: PMID 38347177 · NCT04182724
  16. Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial.
    Chen M, Huang Y, Zhang S, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 38418234 · NCT05821452
  17. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
    Wu D, Li Y, Xu P, et al. · Nat Commun · 2024 · Background
    PubMed: PMID 38467604 · NCT07400094 (NeoCamre-HN) · Squamous Cell Carcinoma of Head and Neck
  18. Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
    Luo L, He Y, Zhu G, et al. · J Hepatocell Carcinoma · 2024 · Background
    PubMed: PMID 36578526 · NCT05717738 (CCGLC-008) · Carcinoma, Hepatocellular
  19. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
    Lin J, Yang X, Long J, et al. · Hepatobiliary Surg Nutr · 2024 · Background
    PubMed: PMID 32832493 · NCT04720131 · Biliary Tract Neoplasms
  20. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
    Li B, Li Y, Zhou H, et al. · Hepatology · 2024 · Background
    PubMed: PMID 37540187 · NCT07314372 (FAD-HCC-001) · Carcinoma, Hepatocellular
  21. Cholangiocarcinoma - evolving concepts and therapeutic strategies.
    Ilyas SI, Khan SA, Hallemeier CL, et al. · Nat Rev Clin Oncol · 2024 · Background
    PubMed: PMID 28994423 · NCT04720131 · Biliary Tract Neoplasms
  22. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
    Cui J, Qin S, Zhou Y, et al. · Signal Transduct Target Ther · 2024 · Background
    PubMed: PMID 39300077 · NCT07521605

2023 (16 papers)

  1. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
    Blay JY, Chevret S, Le Cesne A, et al. · Lancet Oncol · 2023 · Trial result
    PubMed: PMID 37429302 · NCT06140732 · Chordoma
  2. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.
    Zhou Y, Li M, Zhang B, et al. · BMC Med · 2023 · Derived
    PubMed: PMID 38031088 · NCT04074564 · Sarcoma
  3. Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short‑course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer.
    Zhang F, Yu D, Yang J, et al. · Oncol Lett · 2023 · Derived
    PubMed: PMID 37332340 · NCT04928807 · Rectal Neoplasms
  4. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
    Yuan L, Jia GD, Lv XF, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37580352 · NCT04547088 · Nasopharyngeal Carcinoma
  5. Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy.
    Xiao BJ, Sima XX, Chen G, et al. · Cancer Med · 2023 · Derived
    PubMed: PMID 37409613 · NCT03707509 · Nasopharyngeal Carcinoma
  6. Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.
    Lv J, Wu J, Wu H, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 37841441 · NCT05410847 · Stomach Neoplasms
  7. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
    Ding X, Zhang WJ, You R, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36735896 · NCT04586088 · Nasopharyngeal Carcinoma
  8. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
    Ding X, Hua YJ, Zou X, et al. · EClinicalMedicine · 2023 · Derived
    PubMed: PMID 37415845 · NCT04346381
  9. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.
    Yin J, Yuan J, Li Y, et al. · Nat Med · 2023 · Background
    PubMed: PMID 37488287 · NCT06109207 · Squamous Cell Carcinoma of Head and Neck
  10. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
    Tang H, Wang H, Fang Y, et al. · Ann Oncol · 2023 · Background
    PubMed: PMID 36400384 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  11. Cancer statistics, 2023.
    Siegel RL, Miller KD, Wagle NS, et al. · CA Cancer J Clin · 2023 · Background
    PubMed: PMID 36633525 · NCT06109207 · Squamous Cell Carcinoma of Head and Neck
  12. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
    Saba NF, Steuer CE, Ekpenyong A, et al. · Nat Med · 2023 · Background
    PubMed: PMID 37012550 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  13. SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma.
    Lee YM, Chen YH, Ou DL, et al. · J Pathol · 2023 · Background
    PubMed: PMID 36641765 · NCT07521605
  14. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol.
    Huang JT, Zhong JH, Zhang J, et al. · BMJ Open · 2023 · Background
    PubMed: PMID 37770273 · NCT05062837 · Carcinoma, Hepatocellular
  15. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
    Guo Y, Zhang W, Ying J, et al. · Eur J Cancer · 2023 · Background
    PubMed: PMID 36628898 · NCT06148402 · Colorectal Neoplasms
  16. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
    Chiang CL, Chiu KWH, Chan KSK, et al. · Lancet Gastroenterol Hepatol · 2023 · Background
    PubMed: PMID 36529152 · NCT05717738 (CCGLC-008) · Carcinoma, Hepatocellular

2022 (35 papers)

  1. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.
    Zhang Y, Qian L, Chen K, et al. · Mol Ther Oncolytics · 2022 · Trial result
    PubMed: PMID 35399603 · NCT06196671 (PTCA199-8) · Pancreatic Neoplasms
  2. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
    Xu J, Shen J, Gu S, et al. · Clin Cancer Res · 2022 · Trial result
    PubMed: PMID 33087333 · NCT04642664 (ACABC) · Cholangiocarcinoma
  3. Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study.
    Hu Y, Lin H, Hao M, et al. · Cancer Manag Res · 2022 · Trial result
    PubMed: PMID 32753952 · NCT04642664 (ACABC) · Cholangiocarcinoma
  4. Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study.
    Zhou H, Lin L, Qin T, et al. · J Thorac Dis · 2022 · Derived
    PubMed: PMID 34992825 · NCT04541251 · Carcinoma, Non-Small-Cell Lung
  5. Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
    Zhou C, Wang Y, Zhao J, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33323401 · NCT04203485
  6. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
    Zheng Y, Wang Z, Yan C, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 33490196 · NCT04208347 · Adenocarcinoma
  7. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
    Yang Y, Zhu L, Cheng Y, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 35524205 · NCT05043688
  8. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
    Yang K, Han L, Wu S, et al. · Cancer Immunol Immunother · 2022 · Derived
    PubMed: PMID 34689233 · NCT04771715
  9. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
    Xing P, Wang M, Zhao J, et al. · Thorac Cancer · 2022 · Derived
    PubMed: PMID 34409776 · NCT04670913 · Parkinson Disease 4, Autosomal Dominant Lewy Body
  10. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
    Wu SY, Xu Y, Chen L, et al. · Mol Cancer · 2022 · Derived
    PubMed: PMID 35337339 · NCT04129996 · Triple Negative Breast Neoplasms
  11. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
    Wang D, Yang X, Long J, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 33912461 · NCT04642664 (ACABC) · Cholangiocarcinoma
  12. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X, Wu T, Hong Y, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 34998471 · NCT03736863 · Esophageal Neoplasms
  13. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.
    Liu J, Wang Y, Tian Z, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 35641481 · NCT04303741 · Breast Neoplasms
  14. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.
    Lin Z, Cai M, Zhang P, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34725214 · NCT04231552 · Rectal Neoplasms
  15. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
    Ju WT, Xia RH, Zhu DW, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 36104359 · NCT04393506 · Mouth Neoplasms
  16. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
    Jing C, Wang J, Zhu M, et al. · Cancer Immunol Immunother · 2022 · Derived
    PubMed: PMID 35304622 · NCT04345783 · Stomach Neoplasms
  17. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
    Chen L, Jiang YZ, Wu SY, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35247906 · NCT04129996 · Triple Negative Breast Neoplasms
  18. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H, Liu H, Chen Y, et al. · JAMA Surg · 2022 · Background
    PubMed: PMID 34160577 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  19. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
    Weinberg BA, Xiu J, Lindberg MR, et al. · J Gastrointest Oncol · 2022 · Background
    PubMed: PMID 31392046 · NCT04720131 · Biliary Tract Neoplasms
  20. Chordoma.
    Ulici V, Hart J · Arch Pathol Lab Med · 2022 · Background
    PubMed: PMID 34319396 · NCT06140732 · Chordoma
  21. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
    Somaiah N, Conley AP, Parra ER, et al. · Lancet Oncol · 2022 · Background
    PubMed: PMID 35934010 · NCT06140732 · Chordoma
  22. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.
    Solomon B, Callejo A, Bar J, et al. · Cancer Med · 2022 · Background
    PubMed: PMID 35307972 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  23. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F, Liu Y, Zhou X, et al. · Drug Deliv · 2022 · Background
    PubMed: PMID 35506447 · NCT07159217 · Biliary Tract Neoplasms
  24. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
    Rahma OE, Yothers G, Hong TS, et al. · JAMA Oncol · 2022 · Background
    PubMed: PMID 34196693 · NCT07521605
  25. Head and neck cancer.
    Mody MD, Rocco JW, Yom SS, et al. · Lancet · 2022 · Background
    PubMed: PMID 34562395 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  26. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB, Ou FS, Zemla TJ, et al. · JAMA Netw Open · 2022 · Background
    PubMed: PMID 35179586 · NCT06148402 · Colorectal Neoplasms
  27. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
    Jin J, Tang Y, Hu C, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35263150 · NCT07521605
  28. [A new standard is emerging: PD-1 maintenance therapy after neoadjuvant radiochemotherapy and curative resection of oesophageal and AEG carcinomas (CheckMate 577)].
    Hermann RM, Christiansen H · Strahlenther Onkol · 2022 · Background
    PubMed: PMID 34515819 · NCT05184946 · Stomach Neoplasms
  29. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    Garcia-Aguilar J, Patil S, Gollub MJ, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35483010 · NCT07521605
  30. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y, Ajani JA, Kato K, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35108470 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  31. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Dennis MJ, Sacco AG, Qi Y, et al. · Oral Oncol · 2022 · Background
    PubMed: PMID 36279618 · NCT06109207 · Squamous Cell Carcinoma of Head and Neck
  32. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
    DeMaria PJ, Lee-Wisdom K, Donahue RN, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 34479925 · NCT06140732 · Chordoma
  33. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 34887262 · NCT07521605
  34. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A, Lumish M, Sinopoli J, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35660797 · NCT07521605
  35. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, et al. · J Natl Compr Canc Netw · 2022 · Background
    PubMed: PMID 36240850 · NCT07521605

2021 (21 papers)

  1. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
    Xie L, Xu J, Sun X, et al. · J Immunother Cancer · 2021 · Trial result
    PubMed: PMID 32376724 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
    Mei Q, Zhang W, Liu Y, et al. · Clin Cancer Res · 2021 · Trial result
    PubMed: PMID 32499235 · NCT04866862 · Colorectal Neoplasms
  3. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J, Liu Q, Li Y, et al. · J Immunother Cancer · 2021 · Trial result
    PubMed: PMID 32448804 · NCT04642664 (ACABC) · Cholangiocarcinoma
  4. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
    Chiu M, Armstrong EJL, Jennings V, et al. · Expert Opin Biol Ther · 2021 · Trial result
    PubMed: PMID 32067509 · NCT06196671 (PTCA199-8) · Pancreatic Neoplasms
  5. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
    Yang Y, Qu S, Li J, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34174189 · NCT03707509 · Nasopharyngeal Carcinoma
  6. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
    Cheng H, Zong L, Kong Y, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34624252 · NCT04047017 (GTN) · Recurrence
  7. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer.
    Zhu J, Liu A, Sun X, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 33119477 · NCT07521605
  8. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH, Wei XL, Feng J, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 33492986 · NCT04978012 · Nasopharyngeal Carcinoma
  9. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
    Uppaluri R, Campbell KM, Egloff AM, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 32665297 · NCT05213884 · Squamous Cell Carcinoma of Head and Neck
  10. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Rossini D, Lonardi S, Antoniotti C, et al. · Br J Cancer · 2021 · Background
    PubMed: PMID 33024268 · NCT06148402 · Colorectal Neoplasms
  11. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
    Piha-Paul SA, Oh DY, Ueno M, et al. · Int J Cancer · 2021 · Background
    PubMed: PMID 32359091 · NCT04720131 · Biliary Tract Neoplasms
  12. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
    McBride S, Sherman E, Tsai CJ, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 32822275 · NCT04830267 · Nasopharyngeal Carcinoma
  13. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lee NY, Ferris RL, Psyrri A, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33794205 · NCT05213884 · Squamous Cell Carcinoma of Head and Neck
  14. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD, Chung V, Alese OB, et al. · JAMA Oncol · 2021 · Background
    PubMed: PMID 32352498 · NCT04720131 · Biliary Tract Neoplasms
  15. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
    Kelly RJ, Ajani JA, Kuzdzal J, et al. · N Engl J Med · 2021 · Background
    PubMed: PMID 33789008 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  16. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
    Janjigian YY, Shitara K, Moehler M, et al. · Lancet · 2021 · Background
    PubMed: PMID 34102137 · NCT05184946 · Stomach Neoplasms
  17. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS, Ikeda M, Zhu AX, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 32716739 · NCT05062837 · Carcinoma, Hepatocellular
  18. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
    Conroy T, Bosset JF, Etienne PL, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33862000 · NCT07521605
  19. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y, Jia Y, Liu Q, et al. · Ann Palliat Med · 2021 · Background
    PubMed: PMID 34263614 · NCT06140732 · Chordoma
  20. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X, Wu X, Wu H, et al. · J Immunother Cancer · 2021 · Background
    PubMed: PMID 33172881 · NCT04720131 · Biliary Tract Neoplasms
  21. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR, Dijkstra EA, van Etten B, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33301740 · NCT07521605

2020 (21 papers)

  1. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J, Zhang Y, Jia R, et al. · Clin Cancer Res · 2020 · Trial result
    PubMed: PMID 30348638 · NCT04866862 · Colorectal Neoplasms
  2. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
    Qin S, Ren Z, Meng Z, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 32112738 · NCT04642664 (ACABC) · Cholangiocarcinoma
  3. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
    Jacquelot N, Yamazaki T, Roberti MP, et al. · Cell Res · 2020 · Trial result
    PubMed: PMID 31481761 · NCT04866862 · Colorectal Neoplasms
  4. Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
    Franses JW, Hong TS, Zhu AX, et al. · Lancet Gastroenterol Hepatol · 2020 · Trial result
    PubMed: PMID 31109809 · NCT04642664 (ACABC) · Cholangiocarcinoma
  5. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Zheng Y, Yang X, Yan C, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 32171104 · NCT04208347 · Adenocarcinoma
  6. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J, Xu J, Chen Y, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32416073 · NCT03099382 · Esophageal Neoplasms
  7. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
    Zhang XP, Chai ZT, Gao YZ, et al. · HPB (Oxford) · 2020 · Background
    PubMed: PMID 31153833 · NCT04521153 · Carcinoma, Hepatocellular
  8. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
    Xie L, Xu J, Sun X, et al. · Oncologist · 2020 · Background
    PubMed: PMID 30559126 · NCT04044378 · Neoplasms
  9. Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy.
    Wang D, Jia W, Wang Z, et al. · Onco Targets Ther · 2020 · Background
    PubMed: PMID 31410023 · NCT04521153 · Carcinoma, Hepatocellular
  10. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M, Mok TSK, Nishio M, et al. · Lancet Respir Med · 2020 · Background
    PubMed: PMID 30922878 · NCT04547088 · Nasopharyngeal Carcinoma
  11. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
    Raj N, Zheng Y, Kelly V, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31644329 · NCT06831175 · Adrenocortical Carcinoma
  12. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
    Mazzaferro V, Citterio D, Bhoori S, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32615109 · NCT05713994 (CCGLC-001) · Carcinoma, Hepatocellular
  13. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM, Montal R, Villanueva A, et al. · J Hepatol · 2020 · Background
    PubMed: PMID 30943423 · NCT04443309 · Carcinoma, Hepatocellular
  14. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
    Liu C, Jia Q, Wei H, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32888455 · NCT06140732 · Chordoma
  15. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST, Kang JH, Lee J, et al. · Ann Oncol · 2020 · Background
    PubMed: PMID 30785198 · NCT04720131 · Biliary Tract Neoplasms
  16. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
    Kim R, Coppola D, Wang E, et al. · Oncotarget · 2020 · Background
    PubMed: PMID 29805739 · NCT04720131 · Biliary Tract Neoplasms
  17. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M, Li Q, Zou R, et al. · JAMA Oncol · 2020 · Background
    PubMed: PMID 31070690 · NCT04191889 (TRIPLET)
  18. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA, Stephen B, Campbell M, et al. · J Immunother Cancer · 2020 · Background
    PubMed: PMID 31533818 · NCT06831175 · Adrenocortical Carcinoma
  19. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32402160 · NCT05713994 (CCGLC-001) · Carcinoma, Hepatocellular
  20. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
    Ciseł B, Pietrzak L, Michalski W, et al. · Ann Oncol · 2020 · Background
    PubMed: PMID 31192355 · NCT04231552 · Rectal Neoplasms
  21. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
    Akateh C, Black SM, Conteh L, et al. · World J Gastroenterol · 2020 · Background
    PubMed: PMID 31391767 · NCT04521153 · Carcinoma, Hepatocellular

2019 (24 papers)

  1. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
    Zhu J, Armstrong AJ, Friedlander TW, et al. · J Immunother Cancer · 2019 · Trial result
    PubMed: PMID 29368638 · NCT04706598 · Urinary Bladder Neoplasms
  2. Fruquintinib: First Global Approval.
    Shirley M · Drugs · 2019 · Trial result
    PubMed: PMID 30357594 · NCT04866862 · Colorectal Neoplasms
  3. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
    Scott LJ · Drugs · 2019 · Trial result
    PubMed: PMID 29663291 · NCT04642664 (ACABC) · Cholangiocarcinoma
  4. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials.
    Liang L, Wen Y, Hu R, et al. · Cancer Immunol Immunother · 2019 · Trial result
    PubMed: PMID 31451841 · NCT04642664 (ACABC) · Cholangiocarcinoma
  5. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Zhou M, Wang H, Zeng X, et al. · Lancet · 2019 · Background
    PubMed: PMID 31248666 · NCT04521153 · Carcinoma, Hepatocellular
  6. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
    Yang H, Liu H, Chen Y, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 30089078 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  7. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
    Wu J, Lu AD, Zhang LP, et al. · Zhonghua Xue Ye Xue Za Zhi · 2019 · Background
    PubMed: PMID 30704229 · NCT07521605
  8. Hepatocellular Carcinoma.
    Villanueva A · N Engl J Med · 2019 · Background
    PubMed: PMID 30970190 · NCT04443309 · Carcinoma, Hepatocellular
  9. Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
    Tatfi M, Hermine O, Suarez F, et al. · Front Immunol · 2019 · Background
    PubMed: PMID 30662441 · NCT04978012 · Nasopharyngeal Carcinoma
  10. Cancer statistics, 2018.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 29313949 · NCT04720131 · Biliary Tract Neoplasms
  11. Malnutrition is associated with adverse postoperative outcome in patients undergoing elective colorectal cancer resections.
    Seretis C, Kaisari P, Wanigasooriya K, et al. · J BUON · 2019 · Background
    PubMed: PMID 29552757 · NCT07521605
  12. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study.
    Mo H, Huang J, Xu J, et al. · Br J Cancer · 2019 · Background
    PubMed: PMID 29755117 · NCT04947956
  13. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
    McDermott DF, Shah R, Gupte-Singh K, et al. · Qual Life Res · 2019 · Background
    PubMed: PMID 30191365 · NCT04830267 · Nasopharyngeal Carcinoma
  14. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
    Ma BBY, Lim WT, Goh BC, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29584545 · NCT04547088 · Nasopharyngeal Carcinoma
  15. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N, Kong Y, Mu L, et al. · J Hepatol · 2019 · Background
    PubMed: PMID 29471013 · NCT04191889 (TRIPLET)
  16. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
    Lung RW, Hau PM, Yu KH, et al. · J Pathol · 2019 · Background
    PubMed: PMID 29230817 · NCT04978012 · Nasopharyngeal Carcinoma
  17. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY, Wang Y, Xiong Y, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 30082170 · NCT04548271 · Nasopharyngeal Carcinoma
  18. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
    Janjigian YY, Bendell J, Calvo E, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 30110194 · NCT04830267 · Nasopharyngeal Carcinoma
  19. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.
    Huang J, Xu B, Mo H, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29358502 · NCT04947956
  20. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P, Benavides M, Falcó E, et al. · Oncologist · 2019 · Background
    PubMed: PMID 30120161 · NCT06148402 · Colorectal Neoplasms
  21. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
    Ferlay J, Colombet M, Soerjomataram I, et al. · Int J Cancer · 2019 · Background
    PubMed: PMID 30350310 · NCT04521153 · Carcinoma, Hepatocellular
  22. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W, Yang Y, Ma Y, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 30213452 · NCT04830267 · Nasopharyngeal Carcinoma
  23. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B, Harrington KJ, Greil R, et al. · Lancet · 2019 · Background
    PubMed: PMID 31679945 · NCT05213884 · Squamous Cell Carcinoma of Head and Neck
  24. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 30207593 · NCT04947956

2018 (13 papers)

  1. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ, Bagrodia A, Cha EK, et al. · Eur Urol · 2018 · Trial result
    PubMed: PMID 28583311 · NCT04706598 · Urinary Bladder Neoplasms
  2. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    Le DT, Durham JN, Smith KN, et al. · Science · 2018 · Trial result
    PubMed: PMID 28596308 · NCT04866862 · Colorectal Neoplasms
  3. [Incidence and mortality of bladder cancer in China, 2014].
    He YT, Li DJ, Liang D, et al. · Zhonghua Zhong Liu Za Zhi · 2018 · Trial result
    PubMed: PMID 30293387 · NCT04706598 · Urinary Bladder Neoplasms
  4. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.
    Chang SS, Bochner BH, Chou R, et al. · J Oncol Pract · 2018 · Trial result
    PubMed: PMID 28796558 · NCT04706598 · Urinary Bladder Neoplasms
  5. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M, Böhle A, Burger M, et al. · Eur Urol · 2018 · Trial result
    PubMed: PMID 27324428 · NCT04706598 · Urinary Bladder Neoplasms
  6. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L, Guo W, Wang Y, et al. · BMC Cancer · 2018 · Background
    PubMed: PMID 29625604 · NCT04044378 · Neoplasms
  7. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
    Tang Y, Liu Z, Zou Z, et al. · Biomed Res Int · 2018 · Background
    PubMed: PMID 29967789 · NCT06831175 · Adrenocortical Carcinoma
  8. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M, Finn RS, Qin S, et al. · Lancet · 2018 · Background
    PubMed: PMID 29433850 · NCT04443309 · Carcinoma, Hepatocellular
  9. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kang YK, Boku N, Satoh T, et al. · Lancet · 2018 · Background
    PubMed: PMID 28993052 · NCT04225364 · Esophageal Squamous Cell Carcinoma
  10. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
    Jusakul A, Cutcutache I, Yong CH, et al. · Cancer Discov · 2018 · Background
    PubMed: PMID 28667006 · NCT04720131 · Biliary Tract Neoplasms
  11. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    Grothey A, Sobrero AF, Shields AF, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29590544 · NCT07521605
  12. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.
    Dossa F, Chesney TR, Acuna SA, et al. · Lancet Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 28479372 · NCT07521605
  13. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial.
    Chen Q, Shu C, Laurence AD, et al. · Gut · 2018 · Background
    PubMed: PMID 29802174 · NCT04521153 · Carcinoma, Hepatocellular

2017 (5 papers)

  1. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY, Burtness B, Mehra R, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27247226 · NCT05213884 · Squamous Cell Carcinoma of Head and Neck
  2. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
    Manegold C, Dingemans AC, Gray JE, et al. · J Thorac Oncol · 2017 · Background
    PubMed: PMID 27729297 · NCT04720131 · Biliary Tract Neoplasms
  3. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
    Ma W, Gilligan BM, Yuan J, et al. · J Hematol Oncol · 2017 · Background
    PubMed: PMID 27234522 · NCT04443309 · Carcinoma, Hepatocellular
  4. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C, Lee SH, Ejadi S, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28837405 · NCT04547088 · Nasopharyngeal Carcinoma
  5. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    Bauml J, Seiwert TY, Pfister DG, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28328302 · NCT05213884 · Squamous Cell Carcinoma of Head and Neck

2016 (10 papers)

  1. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
    McDermott DF, Sosman JA, Sznol M, et al. · J Clin Oncol · 2016 · Trial result
    PubMed: PMID 26755520 · NCT03912857 · Colorectal Neoplasms
  2. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.
    Kamat AM, Flaig TW, Grossman HB, et al. · Nat Rev Urol · 2016 · Trial result
    PubMed: PMID 25800393 · NCT04706598 · Urinary Bladder Neoplasms
  3. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Zhang L, Huang Y, Hong S, et al. · Lancet · 2016 · Background
    PubMed: PMID 27567279 · NCT04548271 · Nasopharyngeal Carcinoma
  4. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet · 2016 · Background
    PubMed: PMID 26615328 · NCT07521605
  5. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR, Qin R, Seisler DK, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26282635 · NCT07521605
  6. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J, Qin S, Xu J, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26884585 · NCT04548271 · Nasopharyngeal Carcinoma
  7. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL, Blumenschein G, Fayette J, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27718784 · NCT06109207 · Squamous Cell Carcinoma of Head and Neck
  8. Cancer statistics in China, 2015.
    Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26808342 · NCT04521153 · Carcinoma, Hepatocellular
  9. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26361969 · NCT04521153 · Carcinoma, Hepatocellular
  10. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
    Boussiotis VA · N Engl J Med · 2016 · Background
    PubMed: PMID 27806234 · NCT04443309 · Carcinoma, Hepatocellular

2015 (12 papers)

  1. Neoantigens in cancer immunotherapy.
    Schumacher TN, Schreiber RD · Science · 2015 · Trial result
    PubMed: PMID 25838375 · NCT04706598 · Urinary Bladder Neoplasms
  2. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR, Sylvester RJ, Brausi MA, et al. · Eur Urol · 2015 · Trial result
    PubMed: PMID 24948466 · NCT04706598 · Urinary Bladder Neoplasms
  3. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.
    Zandberg DP, Strome SE · Oral Oncol · 2015 · Background
    PubMed: PMID 24819861 · NCT04830267 · Nasopharyngeal Carcinoma
  4. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX, Liu Y, Qin Y, et al. · World J Gastroenterol · 2015 · Background
    PubMed: PMID 25663779 · NCT07521605
  5. Global cancer statistics, 2012.
    Torre LA, Bray F, Siegel RL, et al. · CA Cancer J Clin · 2015 · Background
    PubMed: PMID 25651787 · NCT04521153 · Carcinoma, Hepatocellular
  6. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26254683 · NCT04225364 · Esophageal Squamous Cell Carcinoma
  7. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH, Lee JH, Lim YS, et al. · Gastroenterology · 2015 · Background
    PubMed: PMID 25747273 · NCT04521153 · Carcinoma, Hepatocellular
  8. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
    Golden EB, Demaria S, Schiff PB, et al. · Cancer Immunol Res · 2015 · Background
    PubMed: PMID 24563870 · NCT04830267 · Nasopharyngeal Carcinoma
  9. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Ferlay J, Soerjomataram I, Dikshit R, et al. · Int J Cancer · 2015 · Background
    PubMed: PMID 25220842 · NCT04443309 · Carcinoma, Hepatocellular
  10. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26412456 · NCT04720131 · Biliary Tract Neoplasms
  11. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
    Ang KK, Zhang Q, Rosenthal DI, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25154822 · NCT05213884 · Squamous Cell Carcinoma of Head and Neck
  12. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
    Allemani C, Weir HK, Carreira H, et al. · Lancet · 2015 · Background
    PubMed: PMID 25467588 · NCT04521153 · Carcinoma, Hepatocellular

2014 (8 papers)

  1. Cholangiocarcinoma.
    Razumilava N, Gores GJ · Lancet · 2014 · Trial result
    PubMed: PMID 24581682 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP, Greenberg RE, Steinberg GD, et al. · Urol Oncol · 2014 · Trial result
    PubMed: PMID 22575238 · NCT04706598 · Urinary Bladder Neoplasms
  3. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J · Science · 2014 · Trial result
    PubMed: PMID 24357284 · NCT04706598 · Urinary Bladder Neoplasms
  4. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study.
    Wang SN, Chuang SC, Lee KT, et al. · Hepatol Res · 2014 · Background
    PubMed: PMID 23672310 · NCT04521153 · Carcinoma, Hepatocellular
  5. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature.
    Sharma A, Bode B, Studer G, et al. · Clin Cancer Res · 2014 · Background
    PubMed: PMID 23861514 · NCT04830267 · Nasopharyngeal Carcinoma
  6. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F, Cremolini C, Masi G, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 25337750 · NCT06148402 · Colorectal Neoplasms
  7. Adrenocortical carcinoma.
    Else T, Kim AC, Sabolch A, et al. · Endocr Rev · 2014 · Background
    PubMed: PMID 24423978 · NCT06831175 · Adrenocortical Carcinoma
  8. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
    Deng L, Liang H, Burnette B, et al. · J Clin Invest · 2014 · Background
    PubMed: PMID 24382348 · NCT04830267 · Nasopharyngeal Carcinoma

2013 (2 papers)

  1. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA, Palou J, Soloway M, et al. · BJU Int · 2013 · Trial result
    PubMed: PMID 23452187 · NCT04706598 · Urinary Bladder Neoplasms
  2. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
    Li J, Qin S, Xu J, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 23918952 · NCT04286711

2012 (3 papers)

  1. Immunologic correlates of the abscopal effect in a patient with melanoma.
    Postow MA, Callahan MK, Barker CA, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22397654 · NCT04830267 · Nasopharyngeal Carcinoma
  2. Hepatocellular carcinoma.
    Forner A, Llovet JM, Bruix J, et al. · Lancet · 2012 · Background
    PubMed: PMID 22353262 · NCT04443309 · Carcinoma, Hepatocellular
  3. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M, Terzolo M, Allolio B, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22551107 · NCT06831175 · Adrenocortical Carcinoma

2011 (3 papers)

  1. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Thuss-Patience PC, Kretzschmar A, Bichev D, et al. · Eur J Cancer · 2011 · Trial result
    PubMed: PMID 21742485 · NCT04286711
  2. Global cancer statistics.
    Jemal A, Bray F, Center MM, et al. · CA Cancer J Clin · 2011 · Trial result
    PubMed: PMID 21296855 · NCT04286711
  3. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
    Burnette BC, Liang H, Lee Y, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21300764 · NCT04830267 · Nasopharyngeal Carcinoma

2010 (2 papers)

  1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Valle J, Wasan H, Palmer DH, et al. · N Engl J Med · 2010 · Trial result
    PubMed: PMID 20375404 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    Brahmer JR, Drake CG, Wollner I, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20516446 · NCT04866862 · Colorectal Neoplasms

2009 (5 papers)

  1. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.
    Sebag-Montefiore D, Stephens RJ, Steele R, et al. · Lancet · 2009 · Background
    PubMed: PMID 19269519 · NCT07521605
  2. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
    Kamrava M, Bernstein MB, Camphausen K, et al. · Mol Biosyst · 2009 · Background
    PubMed: PMID 19823740 · NCT07521605
  3. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas.
    Everhart JE, Ruhl CE · Gastroenterology · 2009 · Background
    PubMed: PMID 19245868 · NCT04720131 · Biliary Tract Neoplasms
  4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL, Kang YK, Chen Z, et al. · Lancet Oncol · 2009 · Background
    PubMed: PMID 19095497 · NCT04443309 · Carcinoma, Hepatocellular
  5. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
    André T, Boni C, Navarro M, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19451431 · NCT07521605

2008 (4 papers)

  1. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D, Starling N, Rao S, et al. · N Engl J Med · 2008 · Trial result
    PubMed: PMID 18172173 · NCT04286711
  2. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
    Catalano V, Graziano F, Santini D, et al. · Br J Cancer · 2008 · Trial result
    PubMed: PMID 18971936 · NCT04286711
  3. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
    Vermorken JB, Mesia R, Rivera F, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18784101 · NCT06654297 · Esophageal Squamous Cell Carcinoma
  4. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM, Ricci S, Mazzaferro V, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18650514 · NCT04443309 · Carcinoma, Hepatocellular

2007 (1 paper)

  1. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA, Sebo TJ, Frigola X, et al. · Cancer · 2007 · Trial result
    PubMed: PMID 17340590 · NCT04706598 · Urinary Bladder Neoplasms

2006 (2 papers)

  1. Clinical review: Adrenocortical carcinoma: clinical update.
    Allolio B, Fassnacht M · J Clin Endocrinol Metab · 2006 · Background
    PubMed: PMID 16551738 · NCT06831175 · Adrenocortical Carcinoma
  2. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.
    Abiven G, Coste J, Groussin L, et al. · J Clin Endocrinol Metab · 2006 · Background
    PubMed: PMID 16670169 · NCT06831175 · Adrenocortical Carcinoma

2005 (3 papers)

  1. Novel insights into the mechanism of action of intravesical immunomodulators.
    Mitropoulos DN · In Vivo · 2005 · Trial result
    PubMed: PMID 15875784 · NCT04706598 · Urinary Bladder Neoplasms
  2. Tumor vaccine against recurrence of hepatocellular carcinoma.
    Peng BG, Liang LJ, He Q, et al. · World J Gastroenterol · 2005 · Background
    PubMed: PMID 15655825 · NCT04521153 · Carcinoma, Hepatocellular
  3. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
    Berruti A, Terzolo M, Sperone P, et al. · Endocr Relat Cancer · 2005 · Background
    PubMed: PMID 16172198 · NCT06831175 · Adrenocortical Carcinoma

2004 (3 papers)

  1. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
    Sylvester RJ, Oosterlinck W, van der Meijden AP, et al. · J Urol · 2004 · Trial result
    PubMed: PMID 15126782 · NCT04706598 · Urinary Bladder Neoplasms
  2. Preoperative versus postoperative chemoradiotherapy for rectal cancer.
    Sauer R, Becker H, Hohenberger W, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15496622 · NCT07521605
  3. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.
    Kuang M, Peng BG, Lu MD, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 15014006 · NCT04521153 · Carcinoma, Hepatocellular

2001 (1 paper)

  1. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
    Icard P, Goudet P, Charpenay C, et al. · World J Surg · 2001 · Background
    PubMed: PMID 11572030 · NCT06831175 · Adrenocortical Carcinoma

2000 (1 paper)

  1. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
    Takayama T, Sekine T, Makuuchi M, et al. · Lancet · 2000 · Background
    PubMed: PMID 11022927 · NCT04521153 · Carcinoma, Hepatocellular

1999 (2 papers)

  1. Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer.
    Taniguchi K, Koga S, Nishikido M, et al. · Clin Exp Immunol · 1999 · Trial result
    PubMed: PMID 9933432 · NCT04706598 · Urinary Bladder Neoplasms
  2. Biliary tract cancers.
    de Groen PC, Gores GJ, LaRusso NF, et al. · N Engl J Med · 1999 · Background
    PubMed: PMID 10536130 · NCT04720131 · Biliary Tract Neoplasms

1987 (1 paper)

  1. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Catalona WJ, Hudson MA, Gillen DP, et al. · J Urol · 1987 · Trial result
    PubMed: PMID 3806806 · NCT04706598 · Urinary Bladder Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).